Field Trip Health (CSE: FTRP) is growing up. The company this morning announced that it is set to uplist to the Toronto Stock Exchange as of next week, and will delist from the Canadian Securities Exchange as a result.

The company will see its equity move to the big board as of June 7, 2021, with the firm to continue trading under the symbol “FTRP”. Liekwise, its warrants are to be listed under the symbol “FTRP.wt”. The firms US listing will be unaffected by the move.

As a result of the move, the company has reworked its board of directors slightly, with the appointments of Barry Fishman and Ellen Lubman. Fishman most recently served as the CEO of Vivo Cannabis, prior to which he served as an independent director for Aurora Cannabis and Canopy Growth. Lubman meanwhile is currently chief business officer of Werewolf Therapeutics, prior to which she served in a similar role for Impel NeuroPharma among other roles.

Field Trip Health last traded at $5.03 on the CSE.


Information for this analysis was found via Sedar and Field Trip Health. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

The post Field Trip Health To Uplist To TSX Next Week appeared first on the deep dive.